What Pennant Group's latest earnings tell you
Pennant Group (PNTG) just dropped third quarter numbers that put the spotlight on its home health and hospice expansion, a key driver behind the fresh interest in the stock.
The business reported Q3 2026 sales of US$302.25 million compared with US$229.04 million a year earlier, with net income at US$9.64 million versus US$6.08 million. Basic earnings per share from continuing operations came in at US$0.28, while diluted EPS was US$0.26.
Across the first nine months of 2026, Pennant Group posted sales of US$885.6 million against US$658.38 million in the prior year period, and net income of US$27.24 million compared with US$20.94 million. Basic EPS from continuing operations was US$0.78 and diluted EPS was US$0.76.
The earnings release triggered a sharp reaction, with Pennant Group's share price falling 9.17% on the day to US$40.00 and sliding 5.84% over the past week, even though the year-to-date share price return of 43.73% and 1-year total shareholder return of 68.42% still point to strong longer term momentum.
Compare Pennant Group's momentum and acquisition-driven scale-up with other potential healthcare opportunities by scanning our curated list of 34 healthcare AI stocks .
Pennant Group now appears to be a stronger operator after its acquisitions and earnings beat, while the share price has just slipped significantly. Is this a quality business at a sensible price today?
Most Popular Narrative: 14% Undervalued
The most followed Pennant Group narrative pegs fair value at $46.67, above the latest $40.00 close. This frames the recent share pullback against a still supportive long term thesis built on home based care and acquisitions.
The ongoing shift by payers and families toward lower cost, home based care settings relative to institutional care aligns with Pennant Group's focus on home health and hospice agencies. This can support volume growth and help protect segment margins as demand concentrates in these service lines.
See why 6 investors see Pennant Group as 14% undervalued .
Result: Fair Value of $46.67 (UNDERVALUED)
Still, the Pennant Group story leans heavily on smooth acquisition integration and stable Medicare reimbursement, and setbacks on either front could quickly weaken this 14% undervalued narrative.
Find out about the key risks to this Pennant Group narrative .
Next Steps
Mixed signals about Pennant Group's value and risks can be confusing, so move quickly, review the underlying data, and weigh both sides of the story through 3 key rewards and 1 important warning sign .
Looking for more investment ideas beyond Pennant Group?
Do not stop with Pennant Group. Broaden your watchlist with fresh ideas sourced from Simply Wall Street screeners that spotlight different strengths and risk profiles.
-
Target stronger downside protection by reviewing companies screened for resilience in the 32 resilient stocks with low risk scores .
-
Hunt for potential mispricing opportunities by focusing on quality companies flagged in the 42 high quality undervalued stocks .
-
Spot lesser known opportunities with solid fundamentals by scanning the 21 high quality undiscovered gems .
This article is general in nature and was produced with the assistance of AI automation, based on data and analysis from Simply Wall St. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include PNTG .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
